Uekama Kaneto
Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Yakugaku Zasshi. 2004 Dec;124(12):909-35. doi: 10.1248/yakushi.124.909.
Owing to the increasingly globalized nature of the cyclodextrin (CyD)-related science and technology, development of the CyD-based pharmaceutical formulation is rapidly progressing. The pharmaceutically useful CyDs are classified into hydrophilic, hydrophobic, and ionic derivatives. Because of the multi-functional characteristics and bioadaptability, these CyDs are capable of alleviating the undesirable properties of drug molecules through the formation of inclusion complexes or the form of CyD/drug conjugates. This review outlines the current application of CyDs in drug delivery and pharmaceutical formulation, focusing on the following evidences. 1) The hydrophilic CyDs enhance the rate and extent of bioavailability of poorly water-soluble drugs. 2) The amorphous CyDs such as 2-hydroxypropyl-beta-CyD are useful for inhibition of polymorphic transition and crystallization rates of drugs during storage. 3) The delayed release formulation can be obtained by the use of enteric type CyDs such as O-carboxymethyl-O-ethyl-beta-CyD. 4) The hydrophobic CyDs are useful for modification of the release site and/or time profile of water-soluble drugs with prolonged therapeutic effects. 5) The branched CyDs are particularly effective in inhibiting the adsorption to hydrophobic surface of containers and aggregation of polypeptide and protein drugs. 6) The combined use of different CyDs and/or pharmaceutical additives can serve as more functional drug carriers, improving efficacy and reducing side effects. 7) The CyD/drug conjugates may provide a versatile means for the constructions of not only colonic delivery system but also site-specific drug release system, including gene delivery. On the basis of the above-mentioned knowledge, the advantages and limitations of CyDs in the design of advanced dosage forms will be discussed.
由于环糊精(CyD)相关科学技术日益全球化,基于环糊精的药物制剂开发正在迅速发展。药学上有用的环糊精可分为亲水性、疏水性和离子型衍生物。由于这些环糊精具有多功能特性和生物适应性,它们能够通过形成包合物或环糊精/药物共轭物的形式来减轻药物分子的不良性质。本综述概述了环糊精在药物递送和药物制剂中的当前应用,重点关注以下证据。1)亲水性环糊精可提高难溶性药物的生物利用度速率和程度。2)无定形环糊精,如2-羟丙基-β-环糊精,可用于抑制药物在储存期间的多晶型转变和结晶速率。3)通过使用肠溶型环糊精,如O-羧甲基-O-乙基-β-环糊精,可获得缓释制剂。4)疏水性环糊精可用于修饰水溶性药物的释放部位和/或时间曲线,具有延长的治疗效果。5)支链环糊精在抑制对容器疏水表面的吸附以及多肽和蛋白质药物的聚集方面特别有效。6)不同环糊精和/或药物添加剂的联合使用可作为更具功能性的药物载体,提高疗效并减少副作用。7)环糊精/药物共轭物不仅可为构建结肠递送系统,还可为构建包括基因递送在内的位点特异性药物释放系统提供一种通用方法。基于上述知识,将讨论环糊精在先进剂型设计中的优点和局限性。